Anti-protein phosphatase magnesium-dependent 1A-IgM levels in patients with active ankylosing spondylitis: a potential biomarker

Table 1 Baseline characteristics of AS patients prior to treatment with biologics, compared to RA patients and healthy controls

	AS (n = 28)	RA (n = 28)	p-value*	HC (n = 16)	p-value**
Age, years	33.5 (±11.9)	51.8 (±13.6)	<0.001	35.0 (±9.4)	0.717
Male	25 (89.3)	6 (20)	<0.001	7 (43.8)	0.001
WBC, x10³/uL	7407.1 (±1447.1)	7589.3 (±2601.8)	0.747
ESR, mm/hr	25.5 (21.3–56.0)	25.0 (14.8–50.3)	0.385
CRP, mg/dL	1.25 (0.39–2.14)	0.13 (0.10–0.76)	<0.001
NSAID use			0.042
None	0 (0)	5 (17.9)
As needed	1 (3.6)	0 (0)
Regular use	27 (96.4)	23 (82.1)
DMARD use
Sulfasalazine	26 (92.9)	0 (0)	<0.001
Methotrexate	3 (10.7)	26 (86.7)	<0.001
Hydroxychloroquine	0 (0)	17 (56.7)	<0.001
Leflunomide	0 (0)	1 (3.3)	>0.999
Use of corticosteroid	5 (17.9)	24 (85.7)	<0.001
BASDAI	6.00 (5.35–6.80)
Acute anterior uveitis	6 (21.4)
HLA-B27	27 (96.4)
DAS-28-ESR		4.9 (±1.3)

Values are presented as mean (standard deviation), median (interquartile range) or n (%)
AS ankylosing spondylitis, RA rheumatoid arthritis, HC healthy control, WBC white blood cell count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, NSAID nonsteroidal anti-inflammatory drug, DMARD disease modifying anti-rheumatic drug, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, HLA-B27 human leukocyte antigen-B27, DAS-28-ESR disease activity score-28-erythrocyte sedimentation rate
p-values are indicated as follows: * for AS vs. RA, ** for AS vs. HC

ISSN: 2523-3106